Home › Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma
 

Keywords :   


Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma

2014-12-29 02:22:44| drugdiscoveryonline Home Page

Bio-Path Holdings, Inc., (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, recently announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma

Tags: development holdings initiate lymphoma

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.11STEINBACH40
24.11 Sepua Crue F-170
24.11 SECRET
24.11CRAwith
24.1111/15)&&
24.11 8
24.11
24.11F2023 23
More »